STOCK TITAN

Kronos Bio, Inc. - $KRON STOCK NEWS

Welcome to our dedicated page for Kronos Bio news (Ticker: $KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kronos Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kronos Bio's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
conferences clinical trial
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
none
Kronos Bio, Inc.

Nasdaq:KRON

KRON Rankings

KRON Stock Data

63.10M
43.75M
19.59%
44.68%
1.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN MATEO

About KRON

kronos bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, kronos utilizes its small molecule microarray (smm) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.